| Autor: |
Wrenger, Eike, Muller, Regina, Moesenthin, Michael, Welte, Tobias, Frolich, Jurgen C., Neumann, Klaus H. |
| Předmět: |
|
| Zdroj: |
BMJ: British Medical Journal (International Edition); 7/19/2003, Vol. 327 Issue 7407, p147, 3p, 1 Chart, 1 Graph |
| Abstrakt: |
The article discusses the interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers. The randomised aldactone evaluation study (RALES) proved a substantial (30%) reduction in risk of mortality in patients with severe congestive heart failure by treatment with low dose spironolactone (25-50 mg a day) in addition to standard treatment. Exclusion criteria for treatment in the study were a plasma potassium concentration > 5.0 mmol/l and serum creatinine concentration > 221 μmol/l. Standard treatment for patients with heart failure categorised as New York Heart Association class II to IV includes angiotensin converting enzyme (ACE) inhibitors or angiotensin II AT sub1 receptor antagonists (AT sub1, receptor blockers). |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
